If the Treatment Works, Do We Need to Know Why?: the Promise of Immunotherapy for Experimental Medicine

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2007 Sep 26

PMID 17893205

Citations 8

Authors

Michael R Ehrenstein

Claudia Mauri

Affiliations

Soon will be listed here.

Abstract

There has been much fanfare, and rightly so, heralding a revolution in the treatment of autoimmune disease using biologic agents-antibodies or other molecules that specifically target known mediators of disease. But not all patients respond to even the most successful biologic agent, which may provide clues about alternate disease mechanisms. Studies aimed at understanding the mechanism of action of biologic agents will yield significant benefits for experimental medicine.

Citing Articles

SLE is not a one-size-fits-all disease.

Ehrenstein M, Shipa M J Exp Med. 2023; 220(6).

PMID: 37097613 PMC: 10130747. DOI: 10.1084/jem.20230559.

The interactions between DNA nanostructures and cells: A critical overview from a cell biology perspective.

Frtus A, Smolkova B, Uzhytchak M, Lunova M, Jirsa M, Henry S Acta Biomater. 2022; 146:10-22.

PMID: 35523414 PMC: 9590281. DOI: 10.1016/j.actbio.2022.04.046.

Critical Analysis of Non-Thermal Plasma-Driven Modulation of Immune Cells from Clinical Perspective.

Smolkova B, Frtus A, Uzhytchak M, Lunova M, Kubinova S, Dejneka A Int J Mol Sci. 2020; 21(17).

PMID: 32872159 PMC: 7503900. DOI: 10.3390/ijms21176226.

A Critical Review on Selected External Physical Cues and Modulation of Cell Behavior: Magnetic Nanoparticles, Non-thermal Plasma and Lasers.

Smolkova B, Uzhytchak M, Lynnyk A, Kubinova S, Dejneka A, Lunov O J Funct Biomater. 2018; 10(1).

PMID: 30586923 PMC: 6463085. DOI: 10.3390/jfb10010002.

Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis.

Nguyen D, Cotton A, Attipoe L, Ciurtin C, Dore C, Ehrenstein M J Allergy Clin Immunol. 2018; 142(3):978-980.e9.

PMID: 29935955 PMC: 6127034. DOI: 10.1016/j.jaci.2018.04.026.

References

Lyons J, San M, Happ M, Cross A . B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol. 1999; 29(11):3432-9. DOI: 10.1002/(SICI)1521-4141(199911)29:11<3432::AID-IMMU3432>3.0.CO;2-2. View

Yanaba K, Hamaguchi Y, Venturi G, Steeber D, St Clair E, Tedder T . B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol. 2007; 179(2):1369-80. DOI: 10.4049/jimmunol.179.2.1369. View

Campbell I, ODonnell K, Lawlor K, Wicks I . Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest. 2001; 107(12):1519-27. PMC: 200197. DOI: 10.1172/JCI12724. View

Sandborn W, Hanauer S, Katz S, Safdi M, Wolf D, BAERG R . Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001; 121(5):1088-94. DOI: 10.1053/gast.2001.28674. View

Paroli M, Accapezzato D, Francavilla V, Insalaco A, Plebani A, Balsano F . Long-lasting memory-resting and memory-effector CD4+ T cells in human X-linked agammaglobulinemia. Blood. 2002; 99(6):2131-7. DOI: 10.1182/blood.v99.6.2131. View

Fillatreau S, Sweenie C, McGeachy M, Gray D, Anderton S . B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002; 3(10):944-50. DOI: 10.1038/ni833. View

van den Brande J, Braat H, van den Brink G, Versteeg H, Bauer C, Hoedemaeker I . Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003; 124(7):1774-85. DOI: 10.1016/s0016-5085(03)00382-2. View

Feldmann M, Maini R . Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 2003; 9(10):1245-50. DOI: 10.1038/nm939. View

Vollenhoven R, Harju A, Brannemark S, Klareskog L . Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis. 2003; 62(12):1195-8. PMC: 1754380. DOI: 10.1136/ard.2003.009589. View

10.

Ruddle N, Bergman C, McGrath K, Lingenheld E, GRUNNET M, Padula S . An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med. 1990; 172(4):1193-200. PMC: 2188622. DOI: 10.1084/jem.172.4.1193. View

11.

Selmaj K, Raine C, Cross A . Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol. 1991; 30(5):694-700. DOI: 10.1002/ana.410300510. View

12.

Williams R, Feldmann M, Maini R . Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 1992; 89(20):9784-8. PMC: 50217. DOI: 10.1073/pnas.89.20.9784. View

13.

Mori L, Iselin S, De Libero G, LESSLAUER W . Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol. 1996; 157(7):3178-82. View

14.

Kouskoff V, Korganow A, Duchatelle V, Degott C, Benoist C, Mathis D . Organ-specific disease provoked by systemic autoimmunity. Cell. 1996; 87(5):811-22. DOI: 10.1016/s0092-8674(00)81989-3. View

15.

Wolf S, Dittel B, Hardardottir F, Janeway Jr C . Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med. 1996; 184(6):2271-8. PMC: 2196394. DOI: 10.1084/jem.184.6.2271. View

16.

Korner H, Riminton D, Strickland D, Lemckert F, Pollard J, Sedgwick J . Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med. 1997; 186(9):1585-90. PMC: 2199118. DOI: 10.1084/jem.186.9.1585. View

17.

Svensson L, Jirholt J, Holmdahl R, Jansson L . B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin Exp Immunol. 1998; 111(3):521-6. PMC: 1904879. DOI: 10.1046/j.1365-2249.1998.00529.x. View

18.

. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1999; 53(3):457-65. View

19.

Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y . Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology. 2005; 128(2):376-92. DOI: 10.1053/j.gastro.2004.11.060. View

20.

Brown S, Abreu M . Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease. Curr Opin Drug Discov Devel. 2005; 8(2):160-8. View